Evidence map›Paper›PMID 39852082›Full record

ArticleBiosensors2025

Non-Invasive Point-of-Care Detection of Methamphetamine and Cocaine via Aptamer-Based Lateral Flow Test.

Bilge Erkocyigit, Ezgi Man, Ece Efecan, Ozge Ozufuklar, Deniz Devecioglu, Basak Bagci, Ebru Aldemir, Hakan Coskunol, Serap Evran, Emine Guler Celik

Abstract read
In one paragraph

Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bilge ErkocyigitDepartment of Biotechnology, Institute of Natural Sciences, Ege University, 35040 Izmir, Türkiye.ORCID 0000-0003-1567-9899
Ezgi ManDepartment of Biochemistry, Faculty of Science, Ege University, 35040 Izmir, Türkiye.ORCID 0000-0002-4550-3889
Ece EfecanDepartment of Biotechnology, Institute of Natural Sciences, Ege University, 35040 Izmir, Türkiye.ORCID 0009-0006-4001-2622
Ozge OzufuklarDepartment of Biotechnology, Institute of Natural Sciences, Ege University, 35040 Izmir, Türkiye.ORCID 0009-0005-0722-6955
Deniz DeveciogluDepartment of Psychiatry, Ataturk Educational and Research Hospital, Katip Celebi University, 35360 Izmir, Türkiye.
Basak BagciDepartment of Psychiatry, Ataturk Educational and Research Hospital, Katip Celebi University, 35360 Izmir, Türkiye.
Ebru AldemirDepartment of Psychiatry, Faculty of Medicine, Izmir Tinaztepe University, 35400 Izmir, Türkiye.ORCID 0000-0002-3808-1956
Hakan CoskunolDepartment of Psychiatry, Faculty of Medicine, Ege University, 35040 Izmir, Türkiye.
Serap EvranDepartment of Biochemistry, Faculty of Science, Ege University, 35040 Izmir, Türkiye.ORCID 0000-0001-6676-4888
Emine Guler CelikDepartment of Bioengineering, Faculty of Engineering, Ege University, 35040 Izmir, Türkiye.ORCID 0000-0003-2381-9775

Funding

Scientific and Technological Research Council of Turkey Project no: 221Z083
6 · The paper itself

Abstract

Drug abuse is a major public problem in the workplace, traffic, and forensic issues, which requires a standardized test device to monitor on-site drug use. For field testing, the most important requirements are portability, sensitivity, non-invasiveness, and quick results. Motivated by this problem, a point of care (POC) test based on lateral flow assay (LFA) was developed for the detection of cocaine (COC) and methamphetamine (MET) in saliva which has been selected as the matrix for this study due to its rapid and non-invasive collection process. In the design strategy of an LFA test, the use of gold nanoparticles (AuNPs) with strong optical properties has been combined with the advantages of selecting aptamers under in vitro conditions, making it a highly specific and stable recognition probe for the detection of small molecules in saliva. The developed aptamer-based LFA in a competitive format, was able to detect COC and MET in synthetic saliva at concentrations as low as 5.0 ng/mL. After analytical performance studies, the test system also detected COC and MET in real patient samples, which was verified by chromatographic methods.

Indexed as

Aptamers, NucleotideBiosensing TechniquesCocaineMethamphetaminePoint-of-Care SystemsGoldHumansMetal NanoparticlesSalivaSubstance Abuse DetectionAptamers, NucleotideCocaineGoldMethamphetamineabuse drug testingaptamerlateral flow assaypoint-of-caresaliva drug test

Identifiers

PMID39852082
PMCPMC11764150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.